AtriCure Announces the First Patients Treated with Novel Dual Energy Platform

Atrial Fibrillation Surgery AtriCure develops medical devices and procedures for the surgical treatment of atrial fibrillation. Its products are used by cardiac surgeons to create controlled lesions that interrupt abnormal electrical pathways and restore a more regular heart rhythm. Ablation Technologies The Isolator Synergy Ablation...

Recent company news

ATRCAtriCure2026-07-27 12:00 EST

AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference

ATRCAtriCure2026-05-05 20:01 EST

AtriCure Reports First Quarter 2026 Financial Results

Stock data

Close: 48.98 USD
Market cap: 1.31B USD
Exchange: NASDAQ
Sector: MedTech
Location: United States

AtriCure Announces the First Patients Treated with Novel Dual Energy Platform

Related news

AtriCure to Participate at Upcoming Investor Conferences

AtriCure to Announce Second Quarter 2026 Financial Results

TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease

SeaStar Medical Supports Advances in Critical Care of Pediatric Patients with Acute Kidney Injury (AKI)

Tactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients

Treace Announces First Surgical Case with the HyperPlate™ XM Dynamic Compression Locking Implant System

AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)

Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System

Xtant Medical to Participate in the Canaccord Genuity 46th Annual Growth Conference

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

AtriCure